002755 奥赛康
已收盘 02-06 15:00:00
资讯
新帖
简况
奥赛康:截至1月31日,公司股东人数为34,281户
证券之星 · 02-04
奥赛康:截至1月31日,公司股东人数为34,281户
股市必读:奥赛康(002755)2月2日收盘跌5.42%,主力净流出1075.32万元
证券之星 · 02-03
股市必读:奥赛康(002755)2月2日收盘跌5.42%,主力净流出1075.32万元
股市必读:奥赛康(002755)股东户数3万户,较上期减少2.21%
证券之星 · 01-06
股市必读:奥赛康(002755)股东户数3万户,较上期减少2.21%
每周股票复盘:奥赛康(002755)引进1类新药AN9025
证券之星 · 01-03
每周股票复盘:奥赛康(002755)引进1类新药AN9025
奥赛康最新公告:奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议
证券之星 · 2025-12-29
奥赛康最新公告:奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议
光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事
奥赛康最新公告:子公司注射用德拉沙星葡甲胺获得药品注册证书
证券之星 · 2025-12-22
奥赛康最新公告:子公司注射用德拉沙星葡甲胺获得药品注册证书
奥赛康(002755)12月10日股东户数3.07万户,较上期减少4.12%
证券之星 · 2025-12-22
奥赛康(002755)12月10日股东户数3.07万户,较上期减少4.12%
12月9日奥赛康发布公告,股东减持553.88万股
证券之星 · 2025-12-09
12月9日奥赛康发布公告,股东减持553.88万股
奥赛康:截至11月28日股东人数为32,002户
证券之星 · 2025-12-08
奥赛康:截至11月28日股东人数为32,002户
奥赛康(002755.SZ):创新药利厄替尼片纳入国家医保目录
智通财经 · 2025-12-08
奥赛康(002755.SZ):创新药利厄替尼片纳入国家医保目录
12月5日奥赛康现4笔折价10.25%的大宗交易 合计成交809.42万元
证券之星 · 2025-12-05
12月5日奥赛康现4笔折价10.25%的大宗交易 合计成交809.42万元
12月4日奥赛康现4笔大宗交易 机构净买入1381.5万元
证券之星 · 2025-12-04
12月4日奥赛康现4笔大宗交易 机构净买入1381.5万元
奥赛康:截至11月20日股东人数为33748户
证券日报 · 2025-12-01
奥赛康:截至11月20日股东人数为33748户
12月1日奥赛康现3笔折价10.54%的大宗交易 合计成交1001.4万元
证券之星 · 2025-12-01
12月1日奥赛康现3笔折价10.54%的大宗交易 合计成交1001.4万元
奥赛康(002755)11月10日股东户数3万户,较上期增加9.02%
中金财经 · 2025-11-17
奥赛康(002755)11月10日股东户数3万户,较上期增加9.02%
11月13日奥赛康现14笔折价12.33%的大宗交易 合计成交4659.7万元
证券之星 · 2025-11-13
11月13日奥赛康现14笔折价12.33%的大宗交易 合计成交4659.7万元
股市必读:11月11日奥赛康发布公告,股东减持928.16万股
证券之星 · 2025-11-12
股市必读:11月11日奥赛康发布公告,股东减持928.16万股
股市必读:11月10日奥赛康现10笔折价11.28%的大宗交易 合计成交3235.92万元
证券之星 · 2025-11-11
股市必读:11月10日奥赛康现10笔折价11.28%的大宗交易 合计成交3235.92万元
股市必读:11月5日奥赛康现3笔大宗交易 机构净买入400.76万元
证券之星 · 2025-11-06
股市必读:11月5日奥赛康现3笔大宗交易 机构净买入400.76万元
加载更多
公司概况
公司名称:
北京奥赛康药业股份有限公司
所属行业:
医药制造业
上市日期:
2015-05-15
主营业务:
北京奥赛康药业股份有限公司的主营业务是原料药及制剂的研发、生产、销售。公司的主要产品是抗感染类、抗肿瘤类、慢性病类、消化类、其他类。子公司江苏奥赛康药业有限公司先后被认定为国家高新技术企业、国家技术创新示范企业、国家知识产权示范企业、国家工业企业知识产权运用试点企业,荣获江苏省企业技术创新奖,江苏省科技型领军企业、南京市最具创新力企业。连续16年入选“中国医药研发产品线最佳工业企业”,连续12年入选“中国创新力医药企业20强”榜单。
发行价格:
7.49
{"stockData":{"symbol":"002755","market":"SZ","secType":"STK","nameCN":"奥赛康","latestPrice":16.18,"timestamp":1770361398000,"preClose":16.18,"halted":0,"volume":8203993,"delay":0,"changeRate":0,"floatShares":927999999,"shares":927999999,"eps":0.2765,"marketStatus":"已收盘","change":0,"latestTime":"02-06 15:00:00","open":16.15,"high":16.51,"low":16.02,"amount":134000000,"amplitude":0.0303,"askPrice":16.19,"askSize":243,"bidPrice":16.18,"bidSize":565,"shortable":0,"etf":0,"ttmEps":0.2765,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":16.18,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":17.8,"lowLimit":14.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":928160351,"isCdr":false,"pbRate":4.69,"roa":"--","peRate":58.517179,"roe":"7.13%","epsLYR":0.17,"committee":0.206868,"marketValue":15018000000,"turnoverRate":0.0088,"status":2,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-02-09。","floatMarketCap":15017000000},"requestUrl":"/m/hq/s/002755","defaultTab":"news","newsList":[{"id":"2608650336","title":"奥赛康:截至1月31日,公司股东人数为34,281户","url":"https://stock-news.laohu8.com/highlight/detail?id=2608650336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608650336?lang=zh_cn&edition=full","pubTime":"2026-02-04 11:33","pubTimestamp":1770176036,"startTime":"0","endTime":"0","summary":"证券之星消息,奥赛康(002755)02月03日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止1月31日公司股东人数是多少?谢谢!奥赛康回复:您好!截至1月31日,公司股东人数为34,281户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400016153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2608899212","title":"股市必读:奥赛康(002755)2月2日收盘跌5.42%,主力净流出1075.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608899212","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608899212?lang=zh_cn&edition=full","pubTime":"2026-02-03 01:49","pubTimestamp":1770054549,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘,奥赛康报收于15.7元,下跌5.42%,换手率1.92%,成交量17.8万手,成交额2.87亿元。来自资金流向:2月2日主力资金净流出1075.32万元,游资资金净流入1919.28万元,呈现主力抛售、游资承接格局。交易信息汇总股价提醒2月2日奥赛康收盘报15.7元,跌5.42%,当日成交1780.13万元。前10个交易日资金流向情况:主力资金累计净流出6231.3万元,股价累计下跌12.2%;融资余额累计增加1016.7万元,融券余量累计减少3.46万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300001145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2601317258","title":"股市必读:奥赛康(002755)股东户数3万户,较上期减少2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601317258","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601317258?lang=zh_cn&edition=full","pubTime":"2026-01-06 03:18","pubTimestamp":1767640727,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,奥赛康报收于17.13元,上涨4.9%,换手率1.89%,成交量17.52万手,成交额2.98亿元。交易信息汇总资金流向1月5日主力资金净流入803.17万元;游资资金净流出958.96万元;散户资金净流入155.79万元。股本股东变化股东户数变动近日奥赛康披露,截至2025年12月20日公司股东户数为3.0万户,较12月10日减少679.0户,减幅为2.21%。户均持股数量由上期的3.02万股增加至3.09万股,户均持股市值为51.1万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600002682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2600897098","title":"每周股票复盘:奥赛康(002755)引进1类新药AN9025","url":"https://stock-news.laohu8.com/highlight/detail?id=2600897098","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600897098?lang=zh_cn&edition=full","pubTime":"2026-01-03 04:20","pubTimestamp":1767385220,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,奥赛康报收于16.33元,较上周的16.56元下跌1.39%。本周,奥赛康12月29日盘中最高价报16.58元。江苏奥赛康药业有限公司将与杭州阿诺生物医药科技有限公司签署协议,获得1类创新药AN9025在中国大陆、香港及澳门地区的开发、生产及商业化独占权益。AN9025为新型口服泛RAS抑制剂,拟用于治疗RAS突变型实体瘤,已获中美临床试验批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0028","BK0239"],"gpt_icon":0},{"id":"2595784432","title":"奥赛康最新公告:奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784432","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784432?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:59","pubTimestamp":1767005993,"startTime":"0","endTime":"0","summary":"奥赛康公告称,公司子公司奥赛康药业与阿诺医药达成许可引进协议,将获得阿诺医药在研的1类创新药AN9025项目在许可区域内的开发、生产及商业化的独占权益。奥赛康药业将向阿诺医药支付与若干销售里程碑事件达成相关的付款,总计不超过11.28亿元人民币。AN9025项目为新型口服泛RAS抑制剂,用于治疗RAS突变型实体瘤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900029021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","002755","159992","06978","BK0239","BK1574","BK0028"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面,BD交易后股价不涨反跌成常态?专家:短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易,但从三季度以来,原本利好的消息却不被二级市场买账。最近一周,BD交易再掀一个小高潮。12月22日,先声药业(02096.HK)宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","002755","BK0188","BK0196","LU1328615791.USD","01530","06978","BK1161","03692","603087","LU0502904849.HKD","BK1589","02509","LU2097828557.USD","01167","BK0060","000661","LU0405327148.USD","LU2495084118.USD","BK0012","LU2097828805.USD","BK0239","LU1781817850.SGD","LU1064131003.USD","LU1997244956.HKD","688331","BK0028","688062","BK1574","BK0057","LU1969619763.USD","600276","LU2580892862.HKD","LU2097828631.EUR","01801","LU1997245094.SGD","LU2488822045.USD","LU2097828474.EUR","LU0405327494.USD","LU2148510915.USD","09995","688428","02142","BK1593","LU1997245177.USD","LU1064130708.USD","688336","LU1146622755.USD","LU2097828714.EUR","02096"],"gpt_icon":0},{"id":"2593481842","title":"奥赛康最新公告:子公司注射用德拉沙星葡甲胺获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2593481842","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593481842?lang=zh_cn&edition=full","pubTime":"2025-12-22 19:00","pubTimestamp":1766401205,"startTime":"0","endTime":"0","summary":"奥赛康(002755.SZ)公告称,公司全资子公司江苏奥赛康药业有限公司近日收到国家药品监督管理局核准签发的注射用德拉沙星葡甲胺《药品注册证书》。德拉沙星是新一代广谱抗菌药物,对革兰氏阳性菌、革兰氏阴性菌以及厌氧菌均显示广泛而强大的抗菌活性。注射用德拉沙星葡甲胺独家获批上市后,将进一步丰富公司在抗感染治疗领域的产品组群,在ABSSSI和CABP等适应症中形成差异化竞争优势。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200025225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0028","BK0239"],"gpt_icon":0},{"id":"2593851304","title":"奥赛康(002755)12月10日股东户数3.07万户,较上期减少4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593851304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593851304?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:46","pubTimestamp":1766396811,"startTime":"0","endTime":"0","summary":"证券之星消息,近日奥赛康披露,截至2025年12月10日公司股东户数为3.07万户,较11月28日减少1319.0户,减幅为4.12%。在化学制药行业个股中,奥赛康股东户数低于行业平均水平,截至12月10日,化学制药行业平均股东户数为3.49万户。从股价来看,2025年11月28日至2025年12月10日,奥赛康区间跌幅为2.78%,在此期间股东户数减少1319.0户,减幅为4.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2590104333","title":"12月9日奥赛康发布公告,股东减持553.88万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590104333","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590104333?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:01","pubTimestamp":1765278095,"startTime":"0","endTime":"0","summary":"证券之星消息,12月9日奥赛康发布公告《奥赛康:持股5%以上股东减持计划期限届满暨实施结果的公告》,其股东中亿伟业控股有限公司于2025年11月15日至2025年12月5日间合计减持553.88万股,占公司目前总股本的0.5968%,变动期间该股股价下跌13.26%,截止12月5日收盘报17.08元。股东增减持详情见下表:根据奥赛康2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900030660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002755"],"gpt_icon":0},{"id":"2589384803","title":"奥赛康:截至11月28日股东人数为32,002户","url":"https://stock-news.laohu8.com/highlight/detail?id=2589384803","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589384803?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:15","pubTimestamp":1765181722,"startTime":"0","endTime":"0","summary":"证券之星消息,奥赛康(002755)12月08日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,您好!请问公司截至11月28日收盘公司的股东人数是多少?谢谢奥赛康回复:您好,截至11月28日,公司的股东人数为32,002户,感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800015535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0028","BK0239"],"gpt_icon":0},{"id":"2589801092","title":"奥赛康(002755.SZ):创新药利厄替尼片纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801092","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801092?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:05","pubTimestamp":1765152313,"startTime":"0","endTime":"0","summary":"智通财经APP讯,奥赛康 发布公告,根据国家医疗保障局、人力资源社会保障部于2025年12月7日发布的《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>的通知》,公司产品利厄替尼片纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。利厄替尼片纳入国家医保目录,将进一步提高产品的可及性,有利于产品市场推广,对产品销售起到积极作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002755","BK1574","BK0239","06978","BK1161","BK0028","159992"],"gpt_icon":0},{"id":"2589893185","title":"12月5日奥赛康现4笔折价10.25%的大宗交易 合计成交809.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589893185","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589893185?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:41","pubTimestamp":1764927715,"startTime":"0","endTime":"0","summary":"证券之星消息,12月5日奥赛康发生大宗交易,交易数据如下:近三个月该股共发生53笔大宗交易,合计成交10.7万手,折价成交53笔。该股近期无解禁股上市。截至2025年12月5日收盘,奥赛康(002755)报收于17.08元,上涨0.29%,换手率0.95%,成交量8.8万手,成交额1.48亿元。该股近半年内有股东持股变动,合计净减持1344.6万股,股东增减持明细如下表:该股最近90天内共有2家机构给出评级,买入评级2家;过去90天内机构目标均价为20.23。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500027289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2588002485","title":"12月4日奥赛康现4笔大宗交易 机构净买入1381.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588002485","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588002485?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:58","pubTimestamp":1764838723,"startTime":"0","endTime":"0","summary":"证券之星消息,12月4日奥赛康发生大宗交易,交易数据如下:近三个月该股共发生49笔大宗交易,合计成交10.18万手,折价成交49笔。该股近期无解禁股上市。截至2025年12月4日收盘,奥赛康(002755)报收于17.03元,下跌0.12%,换手率0.74%,成交量6.84万手,成交额1.17亿元。该股近半年内有股东持股变动,合计净减持1344.6万股,股东增减持明细如下表:该股最近90天内共有2家机构给出评级,买入评级2家;过去90天内机构目标均价为20.23。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400025527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0028","BK0239"],"gpt_icon":0},{"id":"2588722093","title":"奥赛康:截至11月20日股东人数为33748户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722093","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588722093?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:04","pubTimestamp":1764590640,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月1日,奥赛康在互动平台回答投资者提问时表示,截至11月20日,公司的股东人数为33748户。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-01/doc-infziehc1915756.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-01/doc-infziehc1915756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2588097723","title":"12月1日奥赛康现3笔折价10.54%的大宗交易 合计成交1001.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588097723","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588097723?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:42","pubTimestamp":1764582146,"startTime":"0","endTime":"0","summary":"证券之星消息,12月1日奥赛康发生大宗交易,交易数据如下:近三个月该股共发生45笔大宗交易,合计成交9.01万手,折价成交45笔。该股近期无解禁股上市。截至2025年12月1日收盘,奥赛康报收于17.74元,上涨0.62%,换手率0.91%,成交量8.49万手,成交额1.51亿元。该股近半年内有股东持股变动,合计净减持1344.6万股,股东增减持明细如下表:该股最近90天内共有3家机构给出评级,买入评级2家,增持评级1家;过去90天内机构目标均价为20.23。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100022418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2584646733","title":"奥赛康(002755)11月10日股东户数3万户,较上期增加9.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584646733","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584646733?lang=zh_cn&edition=full","pubTime":"2025-11-17 17:34","pubTimestamp":1763372063,"startTime":"0","endTime":"0","summary":"证券之星消息,近日奥赛康披露,截至2025年11月10日公司股东户数为3.0万户,较10月20日增加2484.0户,增幅为9.02%。在化学制药行业个股中,奥赛康股东户数低于行业平均水平,截至11月10日,化学制药行业平均股东户数为3.47万户。从股价来看,2025年10月20日至2025年11月10日,奥赛康区间跌幅为4.37%,在此期间股东户数增加2484.0户,增幅为9.02%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202511/17/20251117484743.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202511/17/20251117484743.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251117/31801975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2583504555","title":"11月13日奥赛康现14笔折价12.33%的大宗交易 合计成交4659.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583504555","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583504555?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:21","pubTimestamp":1763025715,"startTime":"0","endTime":"0","summary":"证券之星消息,11月13日奥赛康发生大宗交易,交易数据如下:近三个月该股共发生42笔大宗交易,合计成交8.37万手,折价成交42笔。该股近期无解禁股上市。截至2025年11月13日收盘,奥赛康报收于19.39元,上涨2.92%,换手率2.72%,成交量25.28万手,成交额4.89亿元。该股近半年内有股东持股变动,合计净减持1391.48万股,股东增减持明细如下表:该股最近90天内共有5家机构给出评级,买入评级3家,增持评级2家;过去90天内机构目标均价为20.23。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300029421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2582039444","title":"股市必读:11月11日奥赛康发布公告,股东减持928.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582039444","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582039444?lang=zh_cn&edition=full","pubTime":"2025-11-12 03:53","pubTimestamp":1762890792,"startTime":"0","endTime":"0","summary":"股本股东变化股东增减持11月11日奥赛康发布公告,股东江苏苏洋投资实业有限公司于2025年9月15日至2025年11月10日间合计减持928.16万股,占公司目前总股本的1.0%,变动期间该股股价下跌17.18%,截至11月10日收盘报18.8元。公司公告汇总持股5%以上股东股份变动触及1%的公告北京奥赛康药业股份有限公司持股5%以上股东江苏苏洋投资实业有限公司于2025年9月15日至2025年11月10日期间,通过集中竞价和大宗交易方式累计减持公司股份9,281,600股,占公司总股本的1.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200002930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2582801565","title":"股市必读:11月10日奥赛康现10笔折价11.28%的大宗交易 合计成交3235.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582801565","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582801565?lang=zh_cn&edition=full","pubTime":"2025-11-11 02:18","pubTimestamp":1762798695,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘,奥赛康报收于18.8元,上涨1.46%,换手率1.29%,成交量11.98万手,成交额2.24亿元。交易信息汇总资金流向11月10日主力资金净流入231.75万元;游资资金净流出739.08万元;散户资金净流入507.32万元。大宗交易11月10日奥赛康发生10笔大宗交易,合计成交3235.92万元,平均折价11.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100000886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2581777431","title":"股市必读:11月5日奥赛康现3笔大宗交易 机构净买入400.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581777431","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581777431?lang=zh_cn&edition=full","pubTime":"2025-11-06 01:05","pubTimestamp":1762362316,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘,奥赛康报收于19.05元,下跌0.31%,换手率1.7%,成交量15.76万手,成交额3.04亿元。当日关注点来自交易信息汇总:11月5日主力资金净流入2038.98万元,显示主力对奥赛康的积极介入。来自交易信息汇总:当日发生3笔大宗交易,机构净买入400.76万元,反映机构投资者的增持动向。大宗交易11月5日奥赛康现3笔大宗交易,机构净买入400.76万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600000945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770500907959,"stockEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":-0.0582},{"period":"3month","weight":-0.1268},{"period":"6month","weight":-0.4007},{"period":"1year","weight":0.1982},{"period":"ytd","weight":-0.0092}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京奥赛康药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34281人(较上一季度增加6.84%)","perCapita":"27074股","listingDate":"2015-05-15","address":"北京市丰台区南四环西路188号七区28号楼","registeredCapital":"92816万元","survey":" 北京奥赛康药业股份有限公司的主营业务是原料药及制剂的研发、生产、销售。公司的主要产品是抗感染类、抗肿瘤类、慢性病类、消化类、其他类。子公司江苏奥赛康药业有限公司先后被认定为国家高新技术企业、国家技术创新示范企业、国家知识产权示范企业、国家工业企业知识产权运用试点企业,荣获江苏省企业技术创新奖,江苏省科技型领军企业、南京市最具创新力企业。连续16年入选“中国医药研发产品线最佳工业企业”,连续12年入选“中国创新力医药企业20强”榜单。","listedPrice":7.49},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥赛康(002755)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥赛康(002755)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥赛康,002755,奥赛康股票,奥赛康股票老虎,奥赛康股票老虎国际,奥赛康行情,奥赛康股票行情,奥赛康股价,奥赛康股市,奥赛康股票价格,奥赛康股票交易,奥赛康股票购买,奥赛康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥赛康(002755)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥赛康(002755)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}